Patents by Inventor Chia-Mao Wu
Chia-Mao Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240163407Abstract: A projection system and a control method thereof are provided. The projection system includes a projector. The projector comprises a projection module and a processor. The processor is electrically coupled to the projection module. The projector confirms whether a first triggering event is detected and turns on a sleep aid mode in response to the first triggering event. The sleep aid mode corresponds to at least one control parameter. In the sleep aid mode, the projection module plays at least one multimedia file according to the at least one control parameter. The processor adjusts at least one parameter value of the at least one control parameter to adjust the at least one multimedia file correspondingly. The projector confirms whether a second triggering event is detected and the projection module stops playing the at least one multimedia file and turns off the sleep aid mode in response to the second triggering event.Type: ApplicationFiled: November 1, 2023Publication date: May 16, 2024Applicant: Optoma CorporationInventors: Yuan-Mao Tsui, Hsien-Cheng Yuan, Chia-Chien Wu, Wei-Jung Wang
-
Patent number: 11982860Abstract: An optical member driving mechanism is provided. The optical member driving mechanism includes a fixed portion, a movable portion, an electromagnetic driving assembly and an elastic member. The fixed portion has a base and a frame that is disposed on the base. The movable portion is movable relative to the fixed portion, and includes a carrier for carrying an optical member with an incident optical axis. The carrier includes a body and a sidewall that extends along the edge of the body, wherein the carrier further includes a first stopping portion and a second stopping portion protruding towards the fixed portion. The electromagnetic driving assembly drives the movable portion to move relative to the fixed portion. The movable portion is movably connected to the fixed portion via the elastic member.Type: GrantFiled: April 8, 2022Date of Patent: May 14, 2024Assignee: TDK TAIWAN CORP.Inventors: Chia-Che Wu, Sung-Mao Tsai, Chao-Chang Hu, Che-Wei Chang, Chen-Hsien Fan, Chih-Wei Weng
-
Publication number: 20240141016Abstract: Immunogenic fusion proteins against infectious animal diseases. A fusion protein is disclosed, which comprises a CD40-binding domain; an antigen of a pathogen; a translocation domain located between the CD40-binding domain and the antigen, and a furin and/or cathepsin L cleavage site located between the CD40-binding domain and the translocation domain. Also disclosed are pharmaceutical compositions, expression vectors and use of the fusion proteins of the invention for eliciting an antigen-specific cell-mediated immune response, or for reducing, inhibiting, treating and/or ameliorating an infectious animal disease caused by a pathogen in an animal in need thereof.Type: ApplicationFiled: October 28, 2022Publication date: May 2, 2024Inventor: Chia-Mao WU
-
Patent number: 11914169Abstract: An optical member driving mechanism is provided. The optical member driving mechanism is configured to hold an optical member and drive the optical member to move. The optical member driving mechanism includes a first movable portion, a fixed portion, and a driving assembly. The first movable portion is movable relative to the fixed portion. The driving assembly is configured to drive the first movable portion to move relative to the fixed portion.Type: GrantFiled: January 24, 2020Date of Patent: February 27, 2024Assignee: TDK TAIWAN CORP.Inventors: Chen-Hsien Fan, Sung-Mao Tsai, Chia-Che Wu, Yueh-Lin Lee
-
Publication number: 20210347906Abstract: Fusion proteins for immunotherapy against cancer and infectious diseases are disclosed. A fusion protein according to the invention comprises a CD40-binding domain; an antigen; and a translocation domain located between the CD40-binding domain and the antigen, in which a furin and/or cathepsin L cleavage site is present in the fusion protein between the CD40-binding domain and the translocation domain. The antigen is an antigen of a pathogen or a tumor antigen. The furin and/or cathepsin L cleavage site permits removal of the CD40-binding domain away from the fusion protein via furin and/or cathepsin L cleavage. Also disclosed are pharmaceutical compositions, expression vectors and use of the fusion proteins of the invention for eliciting an antigen-specific cell-mediated immune response, treating a tumor and/or a disease caused by a pathogen in a subject in need thereof.Type: ApplicationFiled: April 26, 2021Publication date: November 11, 2021Inventor: Chia-Mao WU
-
Patent number: 10058606Abstract: A fusion protein for use as a hepatitis B therapeutic vaccine is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen comprising a hepatitis B virus X protein deletion mutant that lacks amino acids (aa) at least from as 21 to as 50. The protein transduction domain is a fusion polypeptide comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide. The APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen is located at the C-terminus of the protein transduction domain.Type: GrantFiled: September 11, 2017Date of Patent: August 28, 2018Assignee: TheVax Genetics Vaccine Co., Ltd.Inventors: Chia-Mao Wu, Jiun-Ming Wu, Yi-Chia Lin, Kung-Lung Lee, Chia-Hao Kang, Fu-Hsien Chiang, Cheng-Yung Chang, Wei-Lun Chang, Hsiang-Kai Lin, Chia-Kuan Peng, Wei-Hsiang Lin, Yi-Tsui Chiu
-
Publication number: 20180078636Abstract: A fusion protein for use as a hepatitis B therapeutic vaccine is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen comprising a hepatitis B virus X protein deletion mutant that lacks amino acids (aa) at least from as 21 to as 50. The protein transduction domain is a fusion polypeptide comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide. The APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen is located at the C-terminus of the protein transduction domain.Type: ApplicationFiled: September 11, 2017Publication date: March 22, 2018Inventors: Chia-Mao WU, Jiun-Ming Wu, Yi-Chia Lin, Kung-Lung Lee, Chia-Hao Kang, Fu-Hsien Chiang, Cheng-Yung Chang, Wei-Lun Chang, Hsiang-Kai Lin, Chia-Kuan Peng, Wei-Hsiang Lin, Yi-Tsui Chiu
-
Patent number: 9775898Abstract: Vaccine compositions for use in inducing enhanced antigen-specific T cell-mediated immune responses in a subject in need thereof are disclosed. The composition comprises (a) a therapeutically effective amount of an immunogenic protein comprising at least an antigen of a pathogen; (b) a saponin-base adjuvant selected from the group consisting of GPI-0100, Quil A, QS-21; and (c) a Toll-like receptor (TLR) agonist adjuvant selected from the group consisting of monophosphoryl lipid A (MPL), and CpG1826.Type: GrantFiled: February 24, 2016Date of Patent: October 3, 2017Assignee: TheVax Genetics Vaccine Co., Ltd.Inventors: Chia-Mao Wu, Jiun-Ming Wu, Yi-Tsui Chiu, Yin-Ching Lin, Hsien-Kai Chuang, Fu-Tan Hsieh, Kuan-Ming Chen
-
Patent number: 9676827Abstract: A fusion protein for use as an immunogen enhancer for enhancing antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen of a pathogen, wherein the APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen of the pathogen is located at the C-terminus of the protein transduction domain. The protein transduction domain is selected from the group consisting of: (i) a fusion polypeptide, comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide; (ii) a T cell-sensitizing signal-transducing peptide; and (iii) a translocation peptide of 34-112 amino acid residues in length.Type: GrantFiled: September 22, 2016Date of Patent: June 13, 2017Assignee: TheVax Genetics Vaccine Co., Ltd.Inventors: Chia-Mao Wu, Hsiu-Kang Chang
-
Patent number: 9676826Abstract: A vaccine composition comprising a fusion protein for inducing enhanced pathogen antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein; (b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, 2, 3, or 6, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and (c) an antigen of a pathogen, located at the C-terminus of the translocation peptide; (d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 13; and (e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein.Type: GrantFiled: April 13, 2016Date of Patent: June 13, 2017Assignee: TheVax Genetics Vaccine Co., Ltd.Inventors: Wei-I Chou, Chia-Mao Wu, Jiun-Ming Wu, Hsiu-Kang Chang
-
Publication number: 20170029470Abstract: A fusion protein for use as an immunogen enhancer for enhancing antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen of a pathogen, wherein the APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen of the pathogen is located at the C-terminus of the protein transduction domain. The protein transduction domain is selected from the group consisting of: (i) a fusion polypeptide, comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide; (ii) a T cell-sensitizing signal-transducing peptide; and (iii) a translocation peptide of 34-112 amino acid residues in length.Type: ApplicationFiled: September 22, 2016Publication date: February 2, 2017Inventors: CHIA-MAO WU, Hsiu-Kang Chang
-
Patent number: 9481714Abstract: A fusion protein for use as an immunogen enhancer for enhancing antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen of a pathogen, wherein the APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen of the pathogen is located at the C-terminus of the protein transduction domain. The protein transduction domain is selected from the group consisting of: (i) a fusion polypeptide, comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide; (ii) a T cell-sensitizing signal-transducing peptide; and (iii) a translocation peptide of 34-112 amino acid residues in length.Type: GrantFiled: December 3, 2013Date of Patent: November 1, 2016Assignee: TheVax Genetics Vaccine Co., Ltd.Inventors: Chia-Mao Wu, Hsiu-Kang Chang
-
Publication number: 20160250324Abstract: Vaccine compositions for use in inducing enhanced antigen-specific T cell-mediated immune responses in a subject in need thereof are disclosed. The composition comprises (a) a therapeutically effective amount of an immunogenic protein comprising at least an antigen of a pathogen; (b) a saponin-base adjuvant selected from the group consisting of GPI-0100, Quil A, QS-21; and (c) a Toll-like receptor (TLR) agonist adjuvant selected from the group consisting of monophosphoryl lipid A (MPL), and CpG1826.Type: ApplicationFiled: February 24, 2016Publication date: September 1, 2016Inventors: Chia-Mao WU, Jiun-Ming Wu, Yi-Tsui Chiu, Yin-Ching Lin, Hsien-Kai Chuang, Fu-Tan Hsieh, Kuan-Ming Chen
-
Publication number: 20160229896Abstract: A vaccine composition comprising a fusion protein for inducing enhanced pathogen antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein; (b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, 2, 3, or 6, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and (c) an antigen of a pathogen, located at the C-terminus of the translocation peptide; (d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 13; and (e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein.Type: ApplicationFiled: April 13, 2016Publication date: August 11, 2016Inventors: WEI-I CHOU, Chia-Mao Wu, Jiun-Ming Wu, Hsiu-Kang Chang
-
Patent number: 9339536Abstract: A vaccine composition comprising a fusion protein for inducing enhanced pathogen antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein; (b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, 2, 3, or 6, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and (c) an antigen of a pathogen, located at the C-terminus of the translocation peptide; (d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 13; and (e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein.Type: GrantFiled: December 3, 2013Date of Patent: May 17, 2016Assignee: TheVax Genetics Vaccine Co., Ltd.Inventors: Wei-I Chou, Chia-Mao Wu, Jiun-Ming Wu, Hsiu-Kang Chang
-
Publication number: 20140154280Abstract: A vaccine composition comprising a fusion protein for inducing enhanced pathogen antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein; (b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, 2, 3, or 6, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and (c) an antigen of a pathogen, located at the C-terminus of the translocation peptide; (d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 13; and (e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein.Type: ApplicationFiled: December 3, 2013Publication date: June 5, 2014Applicant: TheVax Genetics Vaccine Co., Ltd.Inventors: Wei-I CHOU, Chia-Mao Wu, Jiun-Ming Wu, Hsiu-Kang Chang
-
Publication number: 20140154285Abstract: A fusion protein for use as an immunogen enhancer for enhancing antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen of a pathogen, wherein the APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen of the pathogen is located at the C-terminus of the protein transduction domain. The protein transduction domain is selected from the group consisting of: (i) a fusion polypeptide, comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide; (ii) a T cell-sensitizing signal-transducing peptide; and (iii) a translocation peptide of 34-112 amino acid residues in length.Type: ApplicationFiled: December 3, 2013Publication date: June 5, 2014Applicant: TheVax Genetics Vaccine Co., Ltd.Inventors: Chia-Mao WU, Hsiu-Kang Chang